Respiratory Infections

Pneumonia

Community-Acquired Pneumonia (CAP)

•    Common pathogens:

o    Streptococcus pneumoniae (most common)

o    Haemophilus influenzae

o    Atypicals: Mycoplasma pneumoniae, Legionella pneumophila, Chlamydophila pneumoniae

•    Investigations:

o    CXR (lobar consolidation)

o    Sputum culture, blood cultures

o    Urine antigen: Legionella, S. pneumoniae

•    Severity assessment — CURB-65:

o    Confusion (AMT <8)

o    Urea >7 mmol/L

o    Respiratory rate ≥30

o    BP <90 systolic or ≤60 diastolic

o    Age ≥65

o    Score ≥2 consider hospital admission

•    Treatment (based on severity/local guidelines):

o    Mild: amoxicillin ± clarithromycin/doxycycline

o    Moderate/severe: IV co-amoxiclav + clarithromycin


Hospital-Acquired Pneumonia (HAP)

•    Occurs ≥48 hours after hospital admission

•    Common organisms:

o    Gram-negatives: E. coli, Klebsiella, Pseudomonas

o    MRSA

•    Treatment:

o    Early onset (<5 days): co-amoxiclav

o    Late onset or risk of resistance: piperacillin–tazobactam, meropenem ± vancomycin


Empyema

•    Pus in pleural space, often complication of pneumonia

•    Diagnostic features (pleural fluid):

o    pH <7.2

o    glucose

o    LDH

o    Positive Gram stain or culture

•    Management:

o    Chest tube drainage

o    Prolonged antibiotics (2–4 weeks)

o    Surgical referral if loculated


Tuberculosis (TB)

•    Clinical features:

o    Cough >3 weeks, haemoptysis, weight loss, fever, night sweats

o    Risk: immunosuppressed, close contacts, migrants from endemic areas

•    Imaging:

o    CXR: apical infiltrates, cavitation, hilar lymphadenopathy, miliary pattern

•    Diagnosis:

o    Sputum: Ziehl–Neelsen stain (acid-fast bacilli), culture (Lowenstein–Jensen), NAAT

o    IGRA (Interferon Gamma Release Assay): screen latent TB

•    Treatment (RIPE):

o    Rifampicin: orange secretions, enzyme inducer

o    Isoniazid: neurotoxicity give pyridoxine (B6)

o    Pyrazinamide: hepatotoxicity, hyperuricaemia

o    Ethambutol: optic neuritis

o    Duration: 6 months (2 months RIPE, then 4 months R + I)


Bronchiectasis

•    Permanent dilation of bronchi chronic productive cough, recurrent infections

•    Causes:

o    Cystic fibrosis

o    Post-infectious (e.g., measles, pertussis, TB)

o    Primary ciliary dyskinesia (Kartagener’s syndrome)

o    Hypogammaglobulinaemia

•    Diagnosis:

o    HRCT: "tram-track" or "signet-ring" appearance

o    Sputum cultures

•    Management:

o    Chest physiotherapy (postural drainage)

o    Antibiotics (guided by cultures; azithromycin prophylaxis if frequent exacerbations)

o    Bronchodilators if coexisting airflow obstruction


Cystic Fibrosis (CF)

•    Autosomal recessive mutation in CFTR gene (ΔF508 most common)

•    Defective chloride channel thick mucus recurrent infections, pancreatic enzyme insufficiency, male infertility

•    Respiratory: Pseudomonas aeruginosa, S. aureus, bronchiectasis

•    GI: pancreatic insufficiency (fatty stools), CF-related diabetes, meconium ileus in neonates

•    Other: nasal polyps, infertility (bilateral absence of vas deferens)

•    Diagnosis:

o    Newborn screening

o    Sweat chloride test >60 mmol/L

•    Management:

o    Chest physiotherapy, mucolytics (dornase alfa)

o    Antibiotics (oral/inhaled/IV for exacerbations)

o    Pancreatic enzyme replacement

o    CFTR modulators (e.g., ivacaftor, lumacaftor)


Aspergillus-Related Lung Disease

Allergic Bronchopulmonary Aspergillosis (ABPA)

•    Asthma or CF patients

•    Features: wheeze, cough, eosinophilia, fleeting infiltrates, central bronchiectasis

•    Diagnosis:

o    total IgE

o    Positive Aspergillus skin test/IgE/IgG

•    Treatment: steroids ± itraconazole

Aspergilloma

•    Fungal ball in pre-existing cavity (e.g., post-TB)

•    Often asymptomatic but can cause haemoptysis

•    CXR: "air crescent" sign

•    Treatment: surgery if severe haemoptysis

Invasive Aspergillosis

•    Occurs in immunocompromised (e.g., neutropenia, transplant)

•    Features: fever, cough, haemoptysis, pleuritic pain, may disseminate

•    Imaging: halo sign or cavitating nodules on CT

•    Treatment: voriconazole, amphotericin B (severe)



Extra Revision Pearls

•    Rust-coloured sputum S. pneumoniae

•    Dry cough + autoimmune haemolysis Mycoplasma pneumoniae

•    Diarrhoea + hyponatraemia + confusion Legionella

•    CF patients chronic Pseudomonas infection risk, nasal polyps clue

•    Clubbing in bronchiectasis, TB, and lung abscess; uncommon in COPD or asthma

•    Miliary TB think immunosuppression, HIV

•    Empyema pleural fluid glucose often <3.3 mmol/L

•    ABPA clue: asthma patient with fleeting infiltrates + eosinophilia + high IgE

————————————————————————————————————————————————————————————————————————————————————————————————————————-

Author & Educational Disclaimer


Author:

Dr Phillip Cockrell BM FRCP DipClinEd


Dr Phillip Cockrell is a UK Consultant Physician in Internal Medicine, currently working at Queen Alexandra Hospital, Portsmouth University Hospitals NHS Trust. He has previously worked as a registrar across Intensive Care Medicine, Gastroenterology, Cardiology, Stroke Medicine, Acute Medicine, and Respiratory Medicine.


He has held senior leadership roles including Associate Clinical Director of the Acute Medical Unit, Clinical Director of Internal Medicine, and Chief of Medicine. Dr Cockrell has over 15 years’ experience in postgraduate medical education, having lectured extensively across the MRCP syllabus and contributed to MRCP revision teaching and course development.


Dr Cockrell holds a Bachelor of Medicine (BM), Fellowship of the Royal College of Physicians (FRCP), and a Diploma in Clinical Education (DipClinEd). His teaching approach is based on structured consolidation of complex medical topics to support efficient and effective revision for postgraduate examinations.


Purpose of this content:

The material on this page is intended solely for educational purposes to support revision for the MRCP (UK) Part 1 examination. It reflects examination-relevant principles of internal medicine and is designed to aid learning and pattern recognition.


Medical disclaimer:

This content is designed for postgraduate medical examination revision and does not constitute medical advice, diagnosis, or treatment guidance and must not be used as a substitute for professional clinical judgement, local guidelines, or specialist consultation. Clinical decisions should always be made in the context of individual patient circumstances and current national guidance.